Rezolute Inc.

RZLT | NASDAQ

Price Alert Chart Builder DCF Calculator

$3.84

-$0.11 (-2.78%)

At close: Sep 18, 2026, 4:00 PM ET

$3.86

+$0.02 (+0.52%)

Pre-market: Sep 21, 2026, 8:46 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-2.78%

(1D)

Rating

Updated: Aug 15, 2026

21.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $369.76M

1D Range

3.67 3.91

52W Range

1.07 11.46

Valuation (TTM)

PE -4.68

PB 3.16

EV/EBITDA -2.93

Valuation (NTM)

Forward PE N/A

Forward PEG -0.78

Price Target $8.67

Cash Flow

FCF Yield -19.9%

SBC Adj. FCF Yield -22.1%

SBC Impact -11.3%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 15.4% | 31.1%

FCF 3Y | 5Y -18.6% | -19.1%

Returns

ROA -65.0%

ROE -58.8%

ROIC -73.7%

Financial Health

Net Cash

$119.16M

Current Ratio 15.84

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug,...

Sector Healthcare

Industry Biotechnology

Employees 68

IPO Date Jan 13, 2013

Website www.rezolutebio.com

Fiscal Year July - June

Full Company Profile

Latest News

No news articles available yet.

Earnings

Next Earnings

Nov 5, 2026

EPS Est

Pro

Rev Est

Pro

Earnings Details ➞

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+56.25%

Buy (6)

Hold (0)

Sell (0)

Analyst Details ➞